# Prostatype Genomics > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/prostatypegenomics). ## Overview Prostatype Genomics is a Swedish medical technology company focused on molecular diagnostics for prostate cancer. Its core product is the Prostatype® Test System, a gene-expression test used to support treatment decisions after a prostate cancer diagnosis, with commercial activity in selected European markets and the United States. ## Products & services • Prostatype® gene test for prostate cancer prognostication • Prostatype® Test System kit format • Gene-expression analysis from biopsy tissue • Decision-support output for treatment selection • Commercial testing services in selected markets - **Prostatype® diagnostic test** (85%) — Molecular gene test used to assess prostate cancer risk and guide treatment decisions. - **Testing services** (15%) — Commercial testing and related service revenue from running the Prostatype® workflow. - Prostatype® gene test for prostate cancer prognostication - Prostatype® Test System kit format - Gene-expression analysis from biopsy tissue - Decision-support output for treatment selection - Commercial testing services in selected markets ## Customers The company sells into healthcare settings that diagnose and treat prostate cancer, where clinicians need additional information beyond standard pathology. Buyers are typically hospitals, laboratories, and healthcare systems that use the test to support treatment selection and reduce overtreatment. In the U.S., reimbursement and payer acceptance are important because they influence adoption and test utilization. - **Hospitals and specialist clinics** (primary) — Buy the test to support prostate cancer treatment decisions for diagnosed patients - **Clinical laboratories** (secondary) — Use or distribute the test workflow and related sample analysis services - **Payers and reimbursement systems** (primary) — Not direct buyers in all cases, but reimbursement determines uptake and volume - **Physicians and care teams** (primary) — Use the result as decision support when selecting treatment intensity - Hospitals and oncology/urology clinics treating diagnosed prostate cancer - Clinical laboratories that run or distribute the Prostatype® workflow - Healthcare systems seeking better treatment stratification - Payers and reimbursement systems that influence adoption - Physicians needing decision support after biopsy confirmation ## Geography Prostatype Genomics is headquartered in Stockholm, Sweden, and operates from the Swedish market while commercializing its product in selected European markets and the United States. The company’s geography matters because adoption depends on local regulatory clearance, reimbursement pathways, and clinical practice patterns, especially in the U.S. and Europe. - Headquartered in Stockholm, Sweden - Commercial activity in selected European markets - U.S. market is a key commercialization focus - Local reimbursement and regulatory approval shape adoption - Cross-border clinical evidence supports market expansion ## Strategy The company’s strategy centers on commercializing Prostatype® in priority markets and building clinical evidence to support adoption. It also emphasizes reimbursement access, especially in the U.S., while keeping strategic flexibility through partnerships or a potential company sale. - **U.S. commercialization** (short-term) — The U.S. is a large prostate cancer market and a major source of future adoption - **Medicare reimbursement** (short-term) — Reimbursement is central to scaling test volume in the U.S. healthcare system - **Clinical evidence generation** (medium-term) — Published data supports physician confidence, payer coverage, and partner interest - **Strategic partnerships** (medium-term) — Commercial partners can accelerate distribution and market access - Expand Prostatype® commercialization in priority markets - Secure reimbursement to improve adoption and utilization - Strengthen scientific evidence with published studies - Build U.S. commercial traction and payer acceptance - Evaluate collaborations or strategic transaction options ## Risks The business depends on successful commercialization of a single core product, so adoption, reimbursement, and competitive differentiation are critical. It also carries typical medtech risks around regulation, patent challenges, study outcomes, and impairment of capitalized development costs if future cash flows do not materialize as expected. - **Commercialization and adoption risk** [high] — Revenue depends on physicians, labs, and payers adopting Prostatype® at scale - **Reimbursement risk** [high] — Coverage decisions, especially Medicare, affect U.S. test utilization - **Competition and patent challenge risk** [high] — Other medtech companies may launch equivalent tests or challenge IP - **Regulatory and study risk** [high] — Clinical evidence and approvals can be delayed or fail to meet expectations - **Impairment risk on intangible assets** [high] — Capitalized development costs depend on future commercialization cash flows - Single-product dependence increases commercialization risk - Reimbursement delays can slow U.S. adoption and revenue - Patent or IP challenges could weaken market protection - Competitors may develop better or equivalent diagnostics - Capitalized development costs may require impairment ## Accounting A key accounting issue is the valuation of capitalized development costs and other intangible assets, which depend on future commercialization success and cash-flow assumptions. The company also reports under Swedish K3 principles, so investors should watch how management assesses impairment, going-concern assumptions, and any capitalization of development-related spending. - **Capitalized development costs and impairment** — If sales or cash flows disappoint, write-downs may accelerate - **Going-concern and financing assumptions** — Affects liquidity disclosures and continuity assumptions - **K3 accounting framework** — Shapes treatment of development costs, liabilities, and equity - Capitalized development costs are sensitive to impairment testing - Future cash-flow assumptions affect intangible asset valuation - Going-concern assumptions matter until operating cash flow is established - K3 reporting influences presentation of development and financing items --- *Last updated: 2026-08-11T04:04:55.361382+00:00*